Nearly every approved and late-stage obesity drug on the market today, semaglutide, tirzepatide, retatrutide, works through some combination of GLP-1, GIP, glucagon, or amylin receptor activity. GDF15 (growth differentiation factor 15) is a different signaling pathway entirely, and it has become one of the more closely watched targets in early-stage obesity drug research precisely because it doesn't overlap with the mechanisms already on the market.
What GDF15 Is
GDF15 is a naturally occurring hormone, part of the TGF-beta protein family, produced by tissues including skeletal muscle, the liver, and fat tissue. It circulates in the blood and acts on a receptor called GFRAL, located in a part of the brainstem involved in regulating both appetite and nausea. When GDF15 binds GFRAL, it triggers reduced food intake, increased fat burning through effects on mitochondrial function, and improved insulin sensitivity, effects that made it an obvious candidate for obesity drug development once its role was understood.
Why It's Attractive as a Target
The specific appeal of GDF15-based drugs is that the pathway appears to preserve muscle mass better than GLP-1-based therapies, which commonly cause some loss of lean muscle alongside fat loss. Because GDF15 works through a mechanism independent of GLP-1 signaling, researchers are also interested in combination approaches, pairing a GDF15 agonist with an existing GLP-1 drug to potentially get stronger weight loss with less muscle loss than either mechanism alone.
The Nausea Problem
The same brainstem region that GDF15 uses to suppress appetite, the area postrema and nucleus tractus solitarius, is also central to the body's nausea and vomiting reflex. That overlap has been the central challenge in GDF15 drug development: several candidates have produced only modest weight loss in early trials while causing meaningful nausea and vomiting, a worse ratio of benefit to side effect than current GLP-1 drugs have achieved. Researchers have also observed a puzzling resistance pattern, people with obesity tend to have elevated natural GDF15 levels without the expected appetite suppression, suggesting the receptor pathway may become less responsive in obesity, similar to insulin resistance in type 2 diabetes.
Where the Pipeline Stands
Several pharmaceutical companies have GDF15-targeting candidates in early clinical development. Novartis's MBL949 produced only minimal weight reduction after 14 weeks in a Phase 2 trial. Eli Lilly's LY3463251 showed modest weight loss with nausea and vomiting in some participants during Phase 1 testing. Amgen's AMG-171 has shown promising results in animal models but remains in Phase 1 human testing. Other companies, including Janssen and Novo Nordisk, have earlier-stage candidates as well, and at least one preclinical program is exploring a dual GDF15/GLP-1 agonist intended to combine both mechanisms in a single molecule. None of these candidates has reached Phase 3 testing, and none is close to a regulatory submission.
The Bottom Line
GDF15 remains a scientifically interesting but clinically unproven approach to obesity treatment. Its biology explains a real and independent pathway for appetite regulation, but the gap between that biological rationale and a tolerable, effective drug has proven harder to close than early enthusiasm suggested, and no GDF15-targeting therapy is available outside of clinical trials today.
Talk to Your Doctor
As with any investigational compound, GDF15-targeting drugs are not available by prescription, and current FDA-approved obesity treatments remain the appropriate starting point for a conversation with a physician about weight management options.